Free tool
FAERS Monitor: Bendeka
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208194 or its brand name (Bendeka, Bendamustine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
8,502
Serious
7,847
92% of reports
Hospitalization
3,305
Death reported
1,611
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,047
- pyrexia581
- disease progression512
- covid-19412
- drug ineffective405
- product use in unapproved indication404
- febrile neutropenia378
- malignant neoplasm progression363
- neutrophil count decreased360
- neutropenia358
- pneumonia350
- platelet count decreased349
- anaemia325
- death295
- myelosuppression276
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 15 |
| 2012 | 129 |
| 2013 | 46 |
| 2014 | 267 |
| 2015 | 423 |
| 2016 | 544 |
| 2017 | 484 |
| 2018 | 687 |
| 2019 | 624 |
| 2020 | 675 |
| 2021 | 771 |
| 2022 | 1,484 |
| 2023 | 1,043 |
| 2024 | 755 |
| 2025 | 316 |
| 2026 | 233 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,657 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutrophil count decreasedSignal | 360 | 22.0 | 19.9 | 7,159 |
| myelosuppressionSignal | 276 | 19.1 | 17.0 | 4,687 |
| febrile neutropeniaSignal | 378 | 14.2 | 12.8 | 4,603 |
| disease progressionSignal | 512 | 10.7 | 9.9 | 4,522 |
| malignant neoplasm progressionSignal | 363 | 8.8 | 8.0 | 2,504 |
| platelet count decreasedSignal | 349 | 8.1 | 7.3 | 2,177 |
| neutropeniaSignal | 358 | 6.5 | 5.9 | 1,677 |
| covid-19Signal | 412 | 5.8 | 5.3 | 1,650 |
| anaemiaSignal | 325 | 4.2 | 3.8 | 802 |
| pyrexiaSignal | 581 | 4.2 | 3.8 | 1,412 |
| product use in unapproved indicationSignal | 404 | 4.0 | 3.7 | 930 |
| off label useSignal | 1,047 | 3.0 | 2.8 | 1,414 |
| pneumoniaSignal | 350 | 2.7 | 2.4 | 371 |
| death | 295 | 0.8 | 0.8 | 8 |
| drug ineffective | 405 | 0.8 | 0.7 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.